JP2019529467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529467A5 JP2019529467A5 JP2019516182A JP2019516182A JP2019529467A5 JP 2019529467 A5 JP2019529467 A5 JP 2019529467A5 JP 2019516182 A JP2019516182 A JP 2019516182A JP 2019516182 A JP2019516182 A JP 2019516182A JP 2019529467 A5 JP2019529467 A5 JP 2019529467A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- polymer
- per
- layer
- constipation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 132
- 239000003814 drug Substances 0.000 claims description 126
- 229940079593 drug Drugs 0.000 claims description 124
- 239000010410 layer Substances 0.000 claims description 87
- 239000011324 bead Substances 0.000 claims description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 42
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 claims description 41
- 239000007787 solid Substances 0.000 claims description 36
- 229960000345 lubiprostone Drugs 0.000 claims description 35
- 206010010774 Constipation Diseases 0.000 claims description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 229920001577 copolymer Polymers 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 230000004888 barrier function Effects 0.000 claims description 16
- 239000007962 solid dispersion Substances 0.000 claims description 16
- -1 (+)-Isopropyl Chemical group 0.000 claims description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 239000000565 sealant Substances 0.000 claims description 14
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims description 13
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000007771 core particle Substances 0.000 claims description 12
- 239000000454 talc Substances 0.000 claims description 12
- 229910052623 talc Inorganic materials 0.000 claims description 12
- 235000012222 talc Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 208000010643 digestive system disease Diseases 0.000 claims description 10
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 10
- 239000006186 oral dosage form Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 229940072056 alginate Drugs 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 150000000258 13,14-dihydro-15-keto-prostaglandin D2 derivatives Chemical class 0.000 claims description 6
- CTQWVWWSERVGET-HZPDHXFCSA-N 7-[(1r,2r)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O CTQWVWWSERVGET-HZPDHXFCSA-N 0.000 claims description 6
- SDDSJMXGJNWMJY-BRHAQHMBSA-N 7-[(2r,4ar,5r,7ar)-2-[(3s)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid Chemical compound O1[C@](C(F)(F)C[C@@H](C)CC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 SDDSJMXGJNWMJY-BRHAQHMBSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 101000939517 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 2 Proteins 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 102100029643 Ubiquitin carboxyl-terminal hydrolase 2 Human genes 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- KPSZWAJWFMFMFF-UHFFFAOYSA-N hept-5-enoic acid Chemical compound CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 claims description 6
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims description 6
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 4
- 108010062745 Chloride Channels Proteins 0.000 claims description 4
- 102000011045 Chloride Channels Human genes 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 4
- 241000978776 Senegalia senegal Species 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- 239000000440 bentonite Substances 0.000 claims description 4
- 229910000278 bentonite Inorganic materials 0.000 claims description 4
- 235000012216 bentonite Nutrition 0.000 claims description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 235000010216 calcium carbonate Nutrition 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 235000001727 glucose Nutrition 0.000 claims description 4
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 235000021058 soft food Nutrition 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- WIUGSPUQKXSPDJ-JDFMTEHDSA-N (e)-7-[(1r,2r)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1CCC(=O)[C@@H]1CCCC\C=C\C(O)=O WIUGSPUQKXSPDJ-JDFMTEHDSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405131P | 2016-10-06 | 2016-10-06 | |
| US62/405,131 | 2016-10-06 | ||
| PCT/IB2017/001383 WO2018065826A1 (en) | 2016-10-06 | 2017-10-05 | Multilayer beads for pharmaceutical use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529467A JP2019529467A (ja) | 2019-10-17 |
| JP2019529467A5 true JP2019529467A5 (https=) | 2020-09-10 |
| JP6957610B2 JP6957610B2 (ja) | 2021-11-02 |
Family
ID=60543581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516182A Active JP6957610B2 (ja) | 2016-10-06 | 2017-10-05 | 医薬品用途のための多層ビーズ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11534404B2 (https=) |
| JP (1) | JP6957610B2 (https=) |
| AR (1) | AR109898A1 (https=) |
| TW (1) | TW201815383A (https=) |
| WO (1) | WO2018065826A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6957610B2 (ja) | 2016-10-06 | 2021-11-02 | スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ | 医薬品用途のための多層ビーズ |
| CN110022862B (zh) * | 2016-12-09 | 2022-05-24 | 拜耳动物保健有限责任公司 | 药物制剂及其制造方法 |
| WO2019221215A1 (ja) * | 2018-05-18 | 2019-11-21 | ニプロ株式会社 | ルビプロストン含有粒子状医薬組成物 |
| CN109701461B (zh) * | 2018-10-25 | 2021-06-08 | 西南交通大学 | 一种基于PEG/Dex双水相的碳酸钙/海藻酸钙复合微囊的制备及其应用 |
| JP2020075874A (ja) * | 2018-11-06 | 2020-05-21 | ニプロ株式会社 | ルビプロストン含有フィルム状医薬組成物 |
| US20220331257A1 (en) * | 2019-03-01 | 2022-10-20 | Avadel Legacy Pharmaceuticals, Llc | Liquid pharmaceutical compositions with stable drug release profiles |
| JP7518661B2 (ja) * | 2020-05-14 | 2024-07-18 | 沢井製薬株式会社 | ルビプロストン含有整粒物、ルビプロストン含有錠剤およびそれらの製造方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5942313A (ja) * | 1982-09-01 | 1984-03-08 | Teijin Ltd | ポリビニルポリピロリドンを用いた製剤 |
| JPS6377821A (ja) * | 1986-09-19 | 1988-04-08 | Teikoku Seiyaku Kk | 安定なプロスタグランジンｅ組成物 |
| US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| EP0503887B1 (en) | 1991-03-14 | 1996-08-28 | R-Tech Ueno Ltd. | Promotion of wound-healing with 15-keto-prostaglandin compounds |
| RU2695274C3 (ru) | 1999-10-15 | 2020-11-09 | Сукампо Аг | Новые композиции и способы их стабилизации |
| DE19962544A1 (de) | 1999-12-23 | 2001-07-19 | Degussa | Verfahren zum Beschichten eines keramischen Wabenkörpers |
| NZ521784A (en) * | 2000-04-06 | 2005-04-29 | Sucampo Ag | Bile secretion promoting composition |
| US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| WO2002094274A1 (en) | 2001-05-18 | 2002-11-28 | Sucampo Ag | Cathartic composition |
| EP1420794B1 (en) | 2001-08-31 | 2017-12-27 | Sucampo AG | Prostaglandin analogs as chloride channel openers |
| JP2005139085A (ja) * | 2003-11-04 | 2005-06-02 | Ono Pharmaceut Co Ltd | 顆粒 |
| US20080220080A1 (en) * | 2005-03-29 | 2008-09-11 | Röhm Gmbh | Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release |
| CA2637274C (en) * | 2006-01-24 | 2013-06-04 | R-Tech Ueno, Ltd. | Soft-gelatin capsule formulation |
| JP2010502591A (ja) * | 2006-09-04 | 2010-01-28 | パナセア バイオテック リミテッド | プログラム可能な浮揚性送達技術 |
| CN101318948B (zh) * | 2008-04-01 | 2011-04-27 | 上海天伟生物制药有限公司 | 鲁比前列酮晶体、其制备方法及用途 |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| JP4706785B2 (ja) * | 2008-09-30 | 2011-06-22 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
| CA2757979A1 (en) * | 2009-04-09 | 2010-10-14 | Alkermes Pharma Ireland Limited | Controlled-release clozapine compositions |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| US20160120840A1 (en) | 2014-10-30 | 2016-05-05 | Sucampo Ag | Method and composition for treating nonerosive reflux disease |
| EP3463307A4 (en) * | 2016-06-03 | 2020-01-15 | Velicept Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS |
| JP6957610B2 (ja) | 2016-10-06 | 2021-11-02 | スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ | 医薬品用途のための多層ビーズ |
-
2017
- 2017-10-05 JP JP2019516182A patent/JP6957610B2/ja active Active
- 2017-10-05 WO PCT/IB2017/001383 patent/WO2018065826A1/en not_active Ceased
- 2017-10-05 US US16/338,948 patent/US11534404B2/en active Active
- 2017-10-06 AR ARP170102802A patent/AR109898A1/es unknown
- 2017-10-06 TW TW106134584A patent/TW201815383A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529467A5 (https=) | ||
| JP5871886B2 (ja) | 易服用性固形製剤 | |
| AU2013224146B2 (en) | Oral pharmaceutical compositions of dabigatran etexilate | |
| US20100330150A1 (en) | Orally Disintegrating Tablet Compositions Comprising Combinations of High and Low-Dose Drugs | |
| JP5976657B2 (ja) | 易服用性固形製剤 | |
| JP6957610B2 (ja) | 医薬品用途のための多層ビーズ | |
| JP2016512833A (ja) | ウイルス感染症の治療薬としてのベラプロスト異性体 | |
| KR102024699B1 (ko) | 클로피도그렐 및 아스피린을 포함하는 복합제제 | |
| WO2011121823A1 (ja) | 経口投与用粒子状医薬組成物 | |
| JP2012509356A (ja) | ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤 | |
| CA2804874C (en) | Formulations comprising coated fine particles | |
| JP5664225B2 (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
| JP6294400B2 (ja) | 易服用性固形製剤 | |
| JP6688819B2 (ja) | 易服用性固形製剤 | |
| JP2025527009A (ja) | センタナファジン医薬組成物 | |
| JP2006327943A (ja) | 経時的溶出遅延を抑制したテイストマスク錠剤 | |
| WO2023170712A1 (en) | Antiviral pharmaceutical composition | |
| JP2023114903A (ja) | エソメプラゾール含有口腔内崩壊錠の製造方法 | |
| JP2016098187A (ja) | 口腔内崩壊錠 | |
| HK40118462A (zh) | 用於治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷 | |
| HK40055441A (en) | Oral pharmaceutical compositions of dabigatran etexilate | |
| JP2017039763A (ja) | 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠 |